| 產品名稱 |
NCI-H1522 [H1522] |
| 商品貨號 |
B209338 |
| Organism |
Homo sapiens, human |
| Tissue |
lung |
| Product Format |
flask |
| Morphology |
rounded |
| Culture Properties |
mixed adherent-suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
stage E,carcinoma; small cell lung cancer |
| Age |
53 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Applications |
The line was established in October 1986. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
The line was established in October 1986. |
| Clinical Data |
The patient received prior chemotherapy and radiation therapy. The patient was a smoker. male Caucasian 53 years |
| Comments |
The line was established in October 1986. The patient received prior chemotherapy and radiation therapy. The patient was a smoker. 60 pack years. |
| Complete Growth Medium |
HITES medium supplemented with 5% fetal bovine serum
The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No.30-2006. To make the complete growth medium,add the following components to the base medium- 0.005 mg/ml Insulin
- 0.01 mg/ml Transferrin
- 30nM Sodium selenite (final conc.)
- 10 nM Hydrocortisone (final conc.)
- 10 nM beta-estradiol (final conc.)
- extra 2mM L-glutamine (for final conc. of 4.5 mM)
- 5% fetal bovine serum (final conc.)
|
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| STR Profile |
Amelogenin: XY CSF1PO: 10 D13S317: 12 D16S539: 11 D5S818: 11 D7S820: 9, 11, 12 THO1: 7, 9.3 TPOX: 8, 11 vWA: 17, 20 |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| Year of Origin |
1986 |
| References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
